ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,399.22
      -0.51%
      US Tech 100
      18,323.60
      -1.14%
      Dow Jones
      39,935.07
      0.20%
      Brent Oil
      81.535
      0.99%
      Bitcoin
      65,360.81
      -0.03%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU

      6. Argen X SE (ARGX) Quote

      Argen X SE

      Argen X SE (ARGX)

      argenx SE
      443.70
      14.70
      (3.43%)
      Closed July 25 11:30AM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      443.70
      Bid
      440.00
      Ask
      450.00
      Volume
      155,571
      435.60 Day's Range 466.40
      271.00 52 Week Range 493.60
      Market Cap
      26.264B
      Previous Close
      429.00
      Open
      440.00
      Last Trade
      120
      @
      443.7
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      63,785
      Shares Outstanding
      59,194,000
      Dividend Yield
      -
      PE Ratio
      -89.02
      Earnings Per Share (EPS)
      -4.98
      Revenue
      1.27B
      Net Profit
      -295.05M

      About Argen X SE

      Sector
      Coml Physical, Biologcl Resh
      Industry
      Coml Physical, Biologcl Resh
      Website
      www.argenx.com
      Headquarters
      Amsterdam, North Holland, Nld
      Founded
      1970
      Argen X SE is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker ARGX. The last closing price for Argen X was 429.00 €. Over the last year, Argen X shares have traded in a share price range of 271.00 € to 493.60 €.

      Argen X currently has 59,194,000 shares outstanding. The market capitalization of Argen X is 25.39 € billion. Argen X has a price to earnings ratio (PE ratio) of -89.02.

      ARGX Latest News

      More News

      FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

      9 hours ago

      argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

      $478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational...

      16 hours ago
      GlobeNewswire Inc.

      argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

      July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

      July 18 2024
      GlobeNewswire Inc.

      argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

      First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in...

      July 16 2024
      GlobeNewswire Inc.

      argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

      ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of...

      June 25 2024
      GlobeNewswire Inc.

      argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

      VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in...

      June 21 2024
      GlobeNewswire Inc.

      argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

      R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development...

      June 17 2024
      GlobeNewswire Inc.

      argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

      June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

      June 04 2024
      GlobeNewswire Inc.

      argenx Reports First Quarter 2024 Financial Results and Provides Business Update

      $398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in...

      May 09 2024
      GlobeNewswire Inc.

      argenx announces results of Annual General Meeting of Shareholders

      May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe...

      May 07 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      119.54.59688826025424.2466.4419.864559428.36172408DE
      425.26.02150537634418.5466.4398.255330419.9009662DE
      1286.624.2509101092357.1466.4323.463785378.80926381DE
      26107.131.8181818182336.6466.4322.560941367.72920703DE
      52-28.5-6.03557814485472.2493.627160433394.60281026DE
      156175.865.6215005599267.9494.1224.165270347.15633939DE
      260315.2245.291828794128.5494.193.0579038262.94295552DE

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BFIBurgerFi International Inc
      $ 0.5141
      (141.25%)
      		12M
      WINTWindtree Therapeutics Inc
      $ 4.60
      (39.82%)
      		364.99k
      SPECSpectaire Holdings Inc
      $ 0.5459
      (36.48%)
      		5.45M
      CLLSCellectis SA
      $ 2.34
      (14.15%)
      		327.39k
      NUVOHoldco Nuvo Group DG Ltd
      $ 0.80
      (13.80%)
      		45.95k
      DXCMDexCom Inc
      $ 72.40
      (-32.87%)
      		2.93M
      ZYXIZynex Inc
      $ 8.70
      (-14.62%)
      		13.87k
      JEWLAdamas One Corporation
      $ 0.366
      (-10.95%)
      		1.2k
      NVNINVNI Group Ltd
      $ 1.7065
      (-9.71%)
      		181.96k
      TNDMTandem Diabetes Care Inc
      $ 37.00
      (-8.98%)
      		76.52k
      BFIBurgerFi International Inc
      $ 0.5141
      (141.25%)
      		12M
      SPECSpectaire Holdings Inc
      $ 0.5459
      (36.48%)
      		5.45M
      NVDANVIDIA Corporation
      $ 111.56
      (-0.64%)
      		3.86M
      DXCMDexCom Inc
      $ 72.40
      (-32.87%)
      		2.93M
      QDELQuidelOrtho Corporation
      $ 38.24
      (0.00%)
      		2.69M

      Discussion

      View Full Feed
      ipiros ipiros 4 minutes ago
      You are a crook along with your cronies
      HIRU
      CommodityCoverage CommodityCoverage 4 minutes ago
      Summary of Zeus North America Mining's (ZEUS.c) Presentation at the Battery & Precious Metals Virtual Investor Conference: https://x.com/StckMasterFlash/status/1816578501300174849

      Primarily focused on silver and copper, ZEUS has three properties in Idaho with its key flagship property
      ZEUS
      amitgupta amitgupta 4 minutes ago
      Yes i did.
      ViaDerma Provides Highlights of Quarterly Financial ReportThe Company is expanding its staff by hiring new full-time employees
      VDRM
      AtlasQ AtlasQ 4 minutes ago
      I guess tomorrow could be considered the “last day” for us
      RDGL
      Truthfan Truthfan 4 minutes ago
      “He’s not interested”

      A common tactic of the basher gang is to “farm” the message board with questions and accusations designed to “harvest” information from knowledgeable posters.
      NWBO
      Carjockey2 Carjockey2 5 minutes ago
      You're a crook and you've always been a crook nothing's changed run along...
      HIRU
      BigBadWolf BigBadWolf 5 minutes ago
      Good to see you got the invite ;-) as well mi amigo…let’s write a song about the Ihub times :-D
      The best to you & the misses.
      PennyMillions852 PennyMillions852 5 minutes ago
      $IGPK💩💩💩💩💩💩💩💩
      IGPK
      Viewmont Viewmont 5 minutes ago
      Not that it's a big deal/fact. Could be new buyers approaching to close don't want those questions to remain. Who knows, we can go to hundreds of left and right name calling and conclusions. We'll find out.
      HIRU
      tw0122 tw0122 5 minutes ago
      WINT 5.50s
      WINT
      Carjockey2 Carjockey2 6 minutes ago
      POS EOM
      HIRU
      PennyMillions852 PennyMillions852 6 minutes ago
      I thought we were waiting on the Chinese to start buying and this was gonna rocket???👀👀
      IGPK
      12yearplan 12yearplan 6 minutes ago
      LOL,.. hope you don't mind if I drink - sounds like I will need it ;).
      Carjockey2 Carjockey2 6 minutes ago
      You got kicked off of IHub who are you kidding.

      Not on ihub too much but you decided to show up today huh I don't believe in coincidences...

      Funnychit
      HIRU
      Tomorrowneverknows Tomorrowneverknows 6 minutes ago
      Yep us old school know all the players
      HIRU
      OneDayCloser OneDayCloser 6 minutes ago
      Lol
      HIRU
      velcro velcro 7 minutes ago
      Woodside Energy (WDS) is an Australian company listed on the NYSE.
      Annual Dividend is $1.40 which is 7.8% return.
      WDS might be worth an investment since they're stealing TELL.
      TELL executives agreed to a reduced Bonus, but I wonder if that's the price to keep their jobs with Woo
      TELL
      dshade dshade 7 minutes ago
      Are we spread to thin and have too many moving parts, therefore only taking baby steps across 10 different opportunities? No and only 6 opps.
      Do we have enough staff to work on these opportunities? Yes
      Instead, would it make sense to focus on 3? No
      Move those three opportunities
      ECSL
      tw0122 tw0122 7 minutes ago
      WINT 5.32 + 42% 400k float paying cash out some chips
      WINT
      Stinger2014 Stinger2014 7 minutes ago
      This is the time to get back on X Mr. Rice.
      CGAC

      Your Recent History

      EU
      ARGX
      Argen X
      BIT
      UI215B
      Unicredit Bank
      Delayed Upgrade Clock